Literature DB >> 10743454

Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A1 receptors and KATP channel linked mechanisms in rats.

R Kato1, S Ross, P Foëx.   

Abstract

We have investigated if fentanyl protects against myocardial ischaemic injury and if so, if the mechanism of this protection is mediated via opioid and adenosine A1 receptors, and KATP channels. Langendorff rat hearts were subjected to global ischaemia (30 min) and reperfusion (60 min). The drugs were administered before induction of ischaemia and maintained throughout the experiment. Treatment with fentanyl 740 nmol litre-1 improved post-ischaemic mechanical function, assessed as developed pressure, +dP/dtmax and -dP/dtmin, compared with controls after 60 min of reperfusion. These effects were abolished by naloxone 1 mumol litre-1, DPCPX 10 mumol litre-1, a selective adenosine A1 antagonist and sodium 5-hydroxydecanoate 100 mumol litre-1, a K+ATP channel blocker. We conclude that fentanyl protected the heart against post-ischaemic injury by a mechanism which was blocked by an opioid and an adenosine A1 receptor antagonist and also by a KATP channel antagonist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10743454     DOI: 10.1093/oxfordjournals.bja.a013404

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  10 in total

Review 1.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Cardioprotective Effects of Remifentanil in a Sympathetic Hyperactivity Model in Rabbits.

Authors:  Selen Bayındır; Necati Gökmen; Serhat Erbayraktar; Semih Küçükgüçlü; Osman Yılmaz; Ömer Şahin; Elvan Öçmen; Hale Aksu Erdost; Emel Sağıroğlu
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-03-03

4.  Remifentanil-induced preconditioning has cross-talk with A1 and A2B adenosine receptors in ischemic-reperfused rat heart.

Authors:  Yong-Cheol Lee; Jiyoon Jung; Sang-Jin Park
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

Review 5.  Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?

Authors:  P Kleinbongard; G Heusch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 6.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

7.  Morphine and remifentanil-induced cardioprotection: its experimental and clinical outcomes.

Authors:  Jin Mo Kim; Young Ho Jang; Jun Kim
Journal:  Korean J Anesthesiol       Date:  2011-11-23

8.  Effects of remifentanil on hemodynamics, liver function and ICAM-1 expression in liver cancer patients undergoing surgery.

Authors:  Qi Jiang; Xiuling Song; Zheng Chen; Conghui Wang; Huiyu Luo
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

9.  Comparison of lidocaine, huffing maneuver and combination of both in prevention fentanyl induced cough before induction of anesthesia: a double-blind, prospective, randomized placebo-controlled study.

Authors:  Laleh Dehghanpisheh; Mohammadhossein Eghbal; Fatemeh Bagheri Baravati; Pooya Vatankhah
Journal:  BMC Anesthesiol       Date:  2021-03-27       Impact factor: 2.217

Review 10.  Smoking, alcohol and opioids effect on coronary microcirculation: an update overview.

Authors:  Zahra Jalali; Morteza Khademalhosseini; Narjes Soltani; Ali Esmaeili Nadimi
Journal:  BMC Cardiovasc Disord       Date:  2021-04-15       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.